BioHarvest Overview
BioHarvest has developed a technology to produce functional biofood that contains the plants phytochemicals in their natural state, ensuring optimal bioavailability and efficacy. The companys flagship product, VINIA, is a red grape powder that can be consumed directly or mixed with foods or beverages. VINIA provides many of the benefits of drinking red wine without the sugars, calories, and alcohol. BioHarvest uses a clean hydroponic production process that involves no solvent extraction or GMOs and is free of fungicides, pathogens, pesticides, and other residual chemicals. In 2019, the company also started applying its biofarming technology to cannabis plants, with the aim of producing the cannabinoids without the need to grow the cannabis plant itself.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
BioHarvest Sciences positioned for ‘legacy year’ in 2025, building on momentum with new innovations and strategic collaborations
BioHarvest Sciences Inc. is set to leverage key trends in the health and wellness industry, focusing on sustainability, longevity, and plant-based innovation. The company experienced significant growth in 2024, particularly in its direct-to-consumer business, driven by its VINIA product line. BioHarvest plans to expand its product offerings in 2025, including new beverage options and VINIA Super-Chews. The company also aims to strengthen its CDMO services, having formed a key partnership with Tate & Lyle to develop sugar-free sweeteners. BioHarvest anticipates further partnerships in cosmetics, nutraceuticals, and pharmaceuticals, positioning 2025 as a pivotal year for growth and innovation.
Product StageCustomersPartners
growth-positive
BioHarvest Sciences Begins Trading on the Nasdaq Global Market
BioHarvest Sciences Inc., a leader in Botanical Synthesis, has announced its shares will begin trading on the Nasdaq Global Market under the ticker symbol BHST. This move is seen as a significant milestone for the company, expected to elevate its public profile, improve liquidity, and expand its shareholder base. The company will continue trading on the Canadian Securities Exchange. BioHarvest is known for its patented technology platform that grows active ingredients in plants without the need to grow the plant itself. The company is involved in developing therapeutic solutions and nutraceutical products. BioHarvest will release its third-quarter financial results on November 25, 2024, followed by an investor conference call.
Public Trading
BioHarvest Sciences announces a private placement of up to USD $5 million
growth-positive
BioHarvest Sciences Announces a Private Placement of up to CAD $8M of Convertible Notes to Grow Core Business - BioHarvest Sciences
BioHarvest Sciences Inc. has announced a private placement of up to CAD $8 million of two-year convertible notes. The funds raised will primarily support the companys growth in its polyphenols/antioxidants vertical and its R&D program for potentially providing Active Pharmaceutical Ingredients (APIs) to the pharmaceutical industry. The company has provided revenue guidance for 2023 and aims to achieve cash flow breakeven in Q4/2023. BioHarvest Sciences Inc. is focusing on the growth of its core polyphenols business, the development of pharmaceutical-grade cannabis compositions, and the expansion of its clinical studies. The private placement of the notes will be available to qualified investors.
Investment
growth-positive
BIOHARVEST SCIENCES ANNOUNCES CLINICAL STUDY IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED OPTIC NEURITIS - BioHarvest Sciences
BioHarvest Sciences Inc. has announced a collaboration with the International Neurorehabilitation Institute (INI) to perform a clinical trial to assess the capacity of its RGC composition to promote eye health. The study will evaluate the impact of RGC on multiple sclerosis (MS)-related optic neuritis driven by inflammation. The company aims to elucidate the mechanisms through which RGC impacts the disease by measuring anti-oxidative, detoxifying, and inflammatory biomarkers. The study is the first human clinical study to evaluate the combination of health-promoting phytonutrients for the promotion of eye health. The collaboration with INI marks an important step for BioHarvest in creating science-based therapeutic solutions.
PartnersCustomers
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $13.37M |
| Last funding | $5M |
| Stage | Acquired |
| Rounds | 7 |
| Investors | 2 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | bioharvest.com/ |
Locations
Prof. Haim Pekeris St 3, Rehovot, Israel
Vancouver, BC, Canada
Photos & Videos
No files yet
